ObjectiveTo compare the differences between the ultrafiltration method and the dextran gel filtration method during the purification of Tfn-modified PCL micelles by using purification efficiency and micelle purity as indicators. MethodsCoumarin-6 （C6） was used as a fluorescent probe and was loaded into HOOC-PEG-PCL to form PCL micelles by the film-dispersion method. Tfn was then conjugated to the surface of PCL micelles via an amidation reaction， resulting in two types of micelles： Tfn/PCL_H and Tfn/PCL_L. The pharmaceutical properties of the two types of micelles were characterized. The micelles were then purified through ultrafiltration method and dextran gel method respectively， and the efficiency of the two methods， along with the purity of the final micelles， was compared. The density of Tfn on the surface of PCL micelles was also calculated. ResultsThe hydrated diameter of PCL micelles was approximately 73 nm， and the C6 loading efficiency was around 0.046%. The size increased to 134 nm and 158 nm for Tfn/PCL_L and Tfn/PCL_H， respectively. The micelle population was monodisperse. The purification results showed that， for the ultrafiltration method， after two and one rounds of purification， the Tfn/C6 ratio stabilized at 23.6 and 3.4 for Tfn/PCL_H and Tfn/PCL_L， respectively. For the dextran gel filtration method， the Tfn/C6 ratio reached 23.7 for the Tfn/PCL_H group after two rounds of purification. However， for the Tfn/PCL_L group， the Tfn/C6 ratio increased during four rounds of dextran gel purification， and a significant difference （P = 0.042 4） was observed between the first and last filtrations. The density of Tfn in the final micelles were calculated. For the ultrafiltration method， the Tfn density of Tfn/PCL_H and Tfn/PCL_L were 94.9% and 13.8%， respectively. For the dextran gel filtration method， the density of the two micelles were 95.6% and 14.4%， respectively. For Tfn/PCL_L group， the density results revealing a statistically significant difference （P=0.000 2）. ConclusionThe purification efficiency of the two methods is comparable. However， the purity of the final micelles shows a significant difference， with the dextran gel filtration method resulting in higher purity， particularly for the Tfn/PCL_L micelles.

Objective To investigate the early postoperative efficacy between Kahook dual blade(KDB)internal tra-beculectomy and internal gonioscopy-assisted transluminal trabeculotomy(GATT)in the treatment of primary open-angle glaucoma(POAG).Methods A total of 120 patients(120 eyes)with POAG were included and divided according to dif-ferent surgical treatment methods.Among them,62 patients(62 eyes)undergoing internal trabeculectomy by KDB were di-vided into Group A,and 58 patients(58 eyes)undergoing GATT were divided into Group B.Relevant data of patients in the two groups were collected,and the efficacy of the two surgical methods was compared.Results The intraocular pres-sure in both groups decreased 1 day,1 week,and 1 month after surgery compared with preoperative levels(all P＜0.05).However,there was no significant difference in the intraocular pressure measured at the above time points between the two groups(all P＞0.05).The type of drugs for reducing the intraocular pressure in both groups decreased significantly 1 day,1 week,and 1 month after surgery compared with preoperative levels(all P＜0.05).However,there was no significant difference in the type of drugs for reducing the intraocular pressure at the above time points between the two groups(all P＞0.05).There was no statistically significant difference in the total incidence of complications between Group A(45.16％)and Group B(39.66％)(P＞0.05).Specifically,the main complications in Group A included anterior chamber hemorrhage and intraocular pressure rebound,while those in Group B included anterior chamber hemorrhage and ciliary detachment.Conclusion Both KDB internal trabeculectomy and GATT can effectively reduce the intraocular pressure in patients with POAG and reduce the use of postoperative intraocular pressure-lowering drugs.There was no significant difference in surgical complications between the two surgical methods.The selection of surgical procedures in clinical prac-tice can be determined based on patients' wishes and actual situation.

Neurofibromatosis type 1 (NF1) is a hereditary tumor syndrome caused by biallelic inactivation of the tumor suppressor gene NF1 in glial cells in the skin, nerve plexus, or brain, resulting in the development of benign tumors such as cutaneous neurofibromas, plexiform neurofibromas, and gliomas. As the first-line treatment for NF1, surgical treatment has its limitations. Finding more effective non-surgical treatment options has always been the direction of researchers' efforts. However, despite more than 40 years of research, only one drug is currently approved to treat plexiform neurofibromas, and there are no drugs specifically designed to treat other tumors with NF1. Research over the past few years has shown that NF1 patients may benefit from inhibiting different cell signaling pathways in tumor cells, targeting cells in the tumor microenvironment, or currently mature gene therapy. In this review, we provide an overview of nonsurgical treatment options that have previously completed clinical trials, those currently undergoing clinical trials, and recent research advances that may translate into new treatment options for patients with NF1 in the future.

Objective To investigate the clinical efficacy of Modified Yinhuo Guiyuan Huayu Formula(MYGHF)in diabetic retinopathy(DR)patients with yin deficiency and blood stasis syndrome and to observe its regulatory effects on the nuclear factor κB(NF-κB)signaling pathway.Methods A total of 100 DR patients(200 eyes)with yin deficiency and blood stasis syndrome admitted to the Fourth People's Hospital of Hengshui from January 2019 to April 2020 were equally randomized into a control group(50 cases,100 eyes)and an observation group(50 cases,100 eyes)using a random number table.Both groups were required to conduct intensive glycemic control.The control group was treated with conventional western medicine of lecithin-bound iodine,while the observation group received additional MYGHF for 3 months.Parameters of traditional Chinese medicine(TCM)syndrome scores,key components of NF-κB signaling pathway[NF-κB p65,inhibitor of kappa B kinase(IKK),inhibitor kappa B(IκB)],angiogenesis-related factors[fibroblast growth factor 21(FGF21),vascular endothelial growth factor(VEGF),angiopoietin 2(Ang2)],and efficacy indicators[glycated hemoglobin(HbA1c),fasting blood glucose(FBG),homeostasis model assessment of insulin resistance(HOMA-IR),visual field grayscale value,and best-corrected visual acuity(BCVA)]in the two groups were evaluated before treatment and 1 and 3 month(s)after treatment.After treatment,the clinical efficacy and safety of the two groups were assessed.Results(1)After 3 months of treatment,the total effective rate was 88.00%(44/50)in the observation group versus 70.00%(35/50)in the control group,demonstrating significantly superior therapeutic effects of TCM syndrome differentiation in the observation group(tested by chi-square test,P＜0.05).(2)At 1 and 3 month(s)after treatment,both groups showed reduced scores for TCM symptoms of blurred vision,dizziness and tinnitus,soreness and weakness of waist and knees,and feverish sensation in the palms and soles compared to the baseline levels(all P＜0.05).The observation group exhibited significantly greater reductions in these symptom scores than the control group at both time points(all P＜0.05).(3)The protein expression levels of NF-κB p65,IKK were decreased and IκB was increased in both groups at 1 and 3 month(s)after treatment compared to the baseline levels(all P＜0.05),and the observation group demonstrated more pronounced improvement of these key pathway components compared to the control group(all P＜0.05).(4)The levels of angiogenesis-related factors of FGF21,Ang2,and VEGF were significantly reduced in both groups at 1 and 3 month(s)compared to the baseline levels(all P＜0.05),and the observation group showed superior decreases compared to the control group(all P＜0.05).(5)The efficacy indicators of HbA1c,FBG,HOMA-IR,visual field grayscale values,and BCVA were improved in both groups at post-treatment 1 and 3 month(s)compared to the baseline levels(all P＜0.05),and the observation group achieved significantly superior improvement in all indicators compared to the control group(all P＜0.05).(6)The total incidence of adverse reactions was 2.00%(1/50)in the observation group versus 8.00%(4/50)in the control group,with no statistically significant difference between groups(P＞0.05).Conclusion MYGHF effectively alleviates clinical symptoms in patients with DR of yin deficiency and blood stasis type,and is effective on modulating angiogenesis-related factors and suppressing NF-κB signaling pathway activation,demonstrating satisfactory efficacy and good safety profile.

Neurofibromatosis type Ⅰ(NF1) is a hereditary tumor syndrome caused by biallelic inactivation of the tumor suppressor gene NF1 in glial cells in the skin, nerve plexus, or brain, resulting in the development of benign tumors such as cutaneous neurofibromas, plexiform neurofibromas, and gliomas. As the first-line treatment for NF1, surgical treatment has its limitations. The search for more effective non-surgical treatments is ongoing. However, despite more than 40 years of research, only one drug is currently approved to treat plexiform neurofibromas, and there are no drugs specifically designed to treat other tumors with NF1. Research over the past few years has shown that NF1 patients may benefit from inhibiting different cell signaling pathways in tumor cells, targeting cells in the tumor microenvironment, or currently mature gene therapy. In this review, we provide an overview of nonsurgical treatment options that have previously completed clinical trials, those currently undergoing clinical trials, and recent research advances that may translate into new treatment options for patients with NF1 in the future.

Objective To investigate the early postoperative efficacy between Kahook dual blade(KDB)internal tra-beculectomy and internal gonioscopy-assisted transluminal trabeculotomy(GATT)in the treatment of primary open-angle glaucoma(POAG).Methods A total of 120 patients(120 eyes)with POAG were included and divided according to dif-ferent surgical treatment methods.Among them,62 patients(62 eyes)undergoing internal trabeculectomy by KDB were di-vided into Group A,and 58 patients(58 eyes)undergoing GATT were divided into Group B.Relevant data of patients in the two groups were collected,and the efficacy of the two surgical methods was compared.Results The intraocular pres-sure in both groups decreased 1 day,1 week,and 1 month after surgery compared with preoperative levels(all P＜0.05).However,there was no significant difference in the intraocular pressure measured at the above time points between the two groups(all P＞0.05).The type of drugs for reducing the intraocular pressure in both groups decreased significantly 1 day,1 week,and 1 month after surgery compared with preoperative levels(all P＜0.05).However,there was no significant difference in the type of drugs for reducing the intraocular pressure at the above time points between the two groups(all P＞0.05).There was no statistically significant difference in the total incidence of complications between Group A(45.16％)and Group B(39.66％)(P＞0.05).Specifically,the main complications in Group A included anterior chamber hemorrhage and intraocular pressure rebound,while those in Group B included anterior chamber hemorrhage and ciliary detachment.Conclusion Both KDB internal trabeculectomy and GATT can effectively reduce the intraocular pressure in patients with POAG and reduce the use of postoperative intraocular pressure-lowering drugs.There was no significant difference in surgical complications between the two surgical methods.The selection of surgical procedures in clinical prac-tice can be determined based on patients' wishes and actual situation.

Objective To investigate the effect of internal trabeculectomy on postoperative intraocular pressure and visual acuity in patients with primary open angle glaucoma(POAG).Methods A total of 126 POAG patients underwent internal trabeculectomy were included in this study.Intraocular pressure,types of drug used,visual acuity and complications were compared before and after operation.Results Intraocular pressure was significantly decreased,types of drug used were significantly reduced and visual acuity was significantly improved at 1 week,1 month and 3 months after surgery(P＜0.05).The incidence of postoperative intraocular pressure rebound complication was the highest in postoperative patients(27.78%),followed by hyphema(14.29%),corneal edema(10.32%)and ciliary detachment(7.14%).Conclusion Internal trabeculectomy for POAG patients can effectively control the decrease of intraocular pressure in patients,help to restore vision,reduce types of drug used,and the effect is ideal,and the clinical application value is high.

Objective To investigate the effect of internal trabeculectomy on postoperative intraocular pressure and visual acuity in patients with primary open angle glaucoma(POAG).Methods A total of 126 POAG patients underwent internal trabeculectomy were included in this study.Intraocular pressure,types of drug used,visual acuity and complications were compared before and after operation.Results Intraocular pressure was significantly decreased,types of drug used were significantly reduced and visual acuity was significantly improved at 1 week,1 month and 3 months after surgery(P＜0.05).The incidence of postoperative intraocular pressure rebound complication was the highest in postoperative patients(27.78%),followed by hyphema(14.29%),corneal edema(10.32%)and ciliary detachment(7.14%).Conclusion Internal trabeculectomy for POAG patients can effectively control the decrease of intraocular pressure in patients,help to restore vision,reduce types of drug used,and the effect is ideal,and the clinical application value is high.

Neurofibromatosis type 1 (NF1) is a hereditary tumor syndrome caused by biallelic inactivation of the tumor suppressor gene NF1 in glial cells in the skin, nerve plexus, or brain, resulting in the development of benign tumors such as cutaneous neurofibromas, plexiform neurofibromas, and gliomas. As the first-line treatment for NF1, surgical treatment has its limitations. Finding more effective non-surgical treatment options has always been the direction of researchers' efforts. However, despite more than 40 years of research, only one drug is currently approved to treat plexiform neurofibromas, and there are no drugs specifically designed to treat other tumors with NF1. Research over the past few years has shown that NF1 patients may benefit from inhibiting different cell signaling pathways in tumor cells, targeting cells in the tumor microenvironment, or currently mature gene therapy. In this review, we provide an overview of nonsurgical treatment options that have previously completed clinical trials, those currently undergoing clinical trials, and recent research advances that may translate into new treatment options for patients with NF1 in the future.

Neurofibromatosis type Ⅰ(NF1) is a hereditary tumor syndrome caused by biallelic inactivation of the tumor suppressor gene NF1 in glial cells in the skin, nerve plexus, or brain, resulting in the development of benign tumors such as cutaneous neurofibromas, plexiform neurofibromas, and gliomas. As the first-line treatment for NF1, surgical treatment has its limitations. The search for more effective non-surgical treatments is ongoing. However, despite more than 40 years of research, only one drug is currently approved to treat plexiform neurofibromas, and there are no drugs specifically designed to treat other tumors with NF1. Research over the past few years has shown that NF1 patients may benefit from inhibiting different cell signaling pathways in tumor cells, targeting cells in the tumor microenvironment, or currently mature gene therapy. In this review, we provide an overview of nonsurgical treatment options that have previously completed clinical trials, those currently undergoing clinical trials, and recent research advances that may translate into new treatment options for patients with NF1 in the future.